Literature DB >> 21611837

Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.

Xiao Gao1, Chunming Li, Run Zhang, Ruifang Yang, Xiaoyan Qu, Hairong Qiu, Jiaren Xu, Hua Lu, Jianyong Li, Lijuan Chen.   

Abstract

Conventional cytogenetic analysis is often hampered owing to the low mitotic index of multiple myeloma (MM) cells in bone marrow samples of MM. Interphase fluorescence in situ hybridization (I-FISH) analysis combined with magnetic-activated cell sorting (MACS) has substantially enhanced the sensitivity of cytogenetic analysis. Here, we used I-FISH to explore the incidence of chromosomal abnormalities in 60 Chinese patients with newly diagnosed MM. Five different specific probes for the regions containing 13q14.3 (D13S319), 14q32 (IGHC/IGHV), 1q21, 1p12, and 17p13 were used to detect chromosomal aberrations, and LSI IGH/CCND1, LSI IGH/FGFR3, and LSI IGH/MAF probes were further applied to detect t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23) in patients with 14q32 rearrangement. Fifty of the patients (83.3%) had at least one type of abnormalities regarding the regions analyzed. Nine patients (15%) had one abnormality; 10 patients (16.7%) had two abnormalities; 31 patients (51.7%) had three or more abnormalities. The most frequent abnormality in the patients was illegitimate IgH rearrangement (70%), followed by 13q14 deletion (63.3%), 1q21 amplification (61.7%), 1p12 deletion (33.3%), and 17p13 deletion (13.3%). These aberrations are not randomly distributed, but strongly interconnected. Patients with 17p13 deletion or t(4;14)(p16;q32) had significant higher β2-microglobulin level (P < 0.05). However, all these abnormalities had no correlation with age, gender, disease stage, and Ig isotype; yet, it was showed that the frequencies of the individual chromosomal abnormalities were very high. Taken together, MACS in combination with I-FISH may be a promising tool to detect the molecular cytogenetic abnormalities of MM.

Entities:  

Mesh:

Year:  2011        PMID: 21611837     DOI: 10.1007/s12032-011-9988-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  Clinical implications of chromosomal abnormalities in multiple myeloma.

Authors:  Evangelos Terpos; Vangelis Eleutherakis-Papaiakovou; Meletios-Athanassios Dimopoulos
Journal:  Leuk Lymphoma       Date:  2006-05

2.  Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.

Authors:  H M Prince; B Schenkel; L Mileshkin
Journal:  Leukemia       Date:  2007-02-15       Impact factor: 11.528

3.  Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.

Authors:  J Drach; J Schuster; H Nowotny; J Angerler; F Rosenthal; M Fiegl; C Rothermundt; A Gsur; U Jäger; R Heinz
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

4.  Fluorescent in situ hybridization studies in multiple myeloma.

Authors:  Ozge Ozalp Yuregir; Feride Iffet Sahin; Zerrin Yilmaz; Ebru Kizilkilic; Sema Karakus; Hakan Ozdogu
Journal:  Hematology       Date:  2009-04       Impact factor: 2.269

5.  Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma.

Authors:  M Flactif; M Zandecki; J L Laï; F Bernardi; V Obein; F Bauters; T Facon
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

Review 6.  Review of molecular diagnostics in multiple myeloma.

Authors:  A Keith Stewart; Rafael Fonseca
Journal:  Expert Rev Mol Diagn       Date:  2007-07       Impact factor: 5.225

Review 7.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

8.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

Authors:  Nicolaus Kröger; Georgia Schilling; Hermann Einsele; Peter Liebisch; Avichai Shimoni; Arnon Nagler; Jose A Perez-Simon; Jesus F San Miguel; Michael Kiehl; Axel Fauser; Rainer Schwerdtfeger; Hannes Wandt; Herbert G Sayer; Han Myint; Hans Klingemann; Tatjana Zabelina; Judith Dierlamm; Axel Hinke; Axel R Zander
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.

Authors:  Hong Chang; Dan Li; Lihua Zhuang; Eileen Nie; Derek Bouman; A Keith Stewart; Kathy Chun
Journal:  Leuk Lymphoma       Date:  2004-05
View more
  4 in total

1.  New complex chromosome abnormalities in multiple myeloma associated with a poor prognosis: a case report.

Authors:  Agnes C Fett-Conte; Andréa B Carvalho-Salles; Cristina B Vendrame; Patrícia Pedrassa; Paula C Freitas; Marileila Varella-Garcia
Journal:  Leuk Res       Date:  2012-04-12       Impact factor: 3.156

2.  Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.

Authors:  Jihye Ha; Hyunsoo Cho; Taek Gyu Lee; Saeam Shin; Haerim Chung; Ji Eun Jang; Soo-Jeong Kim; June-Won Cheong; Seung-Tae Lee; Jin Seok Kim; Jong Rak Choi
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

3.  High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.

Authors:  Yan Gu; Ya-Hui Yuan; Ji Xu; Qing-Lin Shi; Xiao-Yan Qu; Rui Guo; Hua Bai; Jia-Dai Xu; Jian-Yong Li; Li-Juan Chen
Journal:  Oncotarget       Date:  2017-07-18

4.  Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma.

Authors:  GuoQing Wei; LiJun Wang; HanJin Yang; XiaoYan Han; GaoFeng Zheng; WeiYan Zheng; Jie Sun; JiMin Shi; WenJun Wu; Yi Zhao; DongHua He; Bo Wang; Zhen Cai; JingSong He
Journal:  Exp Hematol Oncol       Date:  2017-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.